BLRX — BioLine RX Cashflow Statement
0.000.00%
Last trade - 00:00- $19.14m
- $6.51m
- $28.94m
- 24
- 59
- 20
- 26
Annual cashflow statement for BioLine RX, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -30 | -27.1 | -25 | -60.6 | -9.22 |
| Depreciation | |||||
| Non-Cash Items | 7.17 | 3.32 | -3.18 | 21.4 | -16.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.29 | -0.54 | 1.24 | 15.2 | -21.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -23.2 | -23.6 | -26.2 | -22.6 | -43.9 |
| Capital Expenditures | 0 | -0.097 | -0.316 | -0.297 | -0.054 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 16.7 | -38.1 | 4.32 | 1.74 | 29.4 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 16.7 | -38.2 | 4.01 | 1.44 | 29.4 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 17.9 | 57.7 | 20.4 | 15.1 | 20.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.5 | -3.84 | -2.4 | -6.33 | 6.18 |